Expect negative price reaction for BIIB and DNLI on the trial failure and discontinuation. Monitor for any further pipeline updates or strategic shifts from Biogen. Denali's independent BEACON study in LRRK2 carriers may provide partial offset.
Price Chart
Executive Summary
Biogen and Denali announced that the Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease failed to meet its primary and secondary endpoints. Development of BIIB122 for idiopathic Parkinson's disease will be discontinued, a significant setback for Biogen's pipeline.
Key Facts
- Phase 2b LUMA study of BIIB122 did not meet primary endpoint of Time to Confirmed Worsening in MDS-UPDRS Part II and III combined score.
- Secondary endpoints also did not show benefit with BIIB122.
- Biogen and Denali will discontinue further development of BIIB122 in idiopathic Parkinson's disease.
- Denali continues Phase 2a BEACON study in LRRK2 variant carriers independently.
- BIIB122 was generally well tolerated with >90% kinase inhibition achieved.
Financial Impact
Development costs and potential write-offs for BIIB122, but no specific dollar amounts disclosed in the press release.
Risk Factors
- Loss of potential revenue from BIIB122 in idiopathic Parkinson's disease.
- Reduced investor confidence in Biogen's pipeline efficiency.
- Potential impairment of collaboration assets.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299820 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 28d ago | Press Release | $220.83 $217.36 | ▼ −1.57% | ▼ −0.36% | $219.88 (−0.43%) |
Sep 3, 2026 29d ago | Press Release | $224.51 $217.15 | ▼ −3.28% | ▼ −2.13% | $219.88 (−2.06%) |
Aug 6, 2026 8w ago | Press Release | $207.94 $209.83 | ▲ +0.91% | ▲ +0.51% | $219.88 (+5.74%) |
Jul 14, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | Press Release | $191.95 $199.95 | ▲ +4.17% | ▲ +5.46% | $219.88 (+14.55%) |
Jul 13, 2026 11w ago | ANALYST-UPGRADE | — | awaiting T+5 | — | — |
Jun 17, 2026 15w ago | Press Release | $196.58 $201.96 | ▲ +2.74% | ▲ +4.40% | $219.88 (+11.85%) |
Jun 8, 2026 16w ago | ANALYST-UPGRADE | $192.62 $198.64 | ▲ +3.13% | ▲ +1.01% | $219.88 (+14.15%) |
Jun 4, 2026 17w ago | Press Release | $195.82 $199.96 | ▲ +2.12% | ▲ +4.67% | $219.88 (+12.29%) |
Jun 1, 2026 17w ago | Press Release | $192.22 $195.34 | ▲ +1.63% | ▲ +4.38% | $219.88 (+14.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access